Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
07 Février 2024 - 2:00PM
Pacira BioSciences, Inc., (Nasdaq: PCRX), the industry leader in
its commitment to non-opioid pain management and regenerative
health solutions, has been awarded a national group purchasing
agreement for Brand Pharmaceuticals with Premier, Inc. Effective
January 1, 2024, the new agreement allows Premier members, at their
discretion, to take advantage of special pricing and terms
pre-negotiated by Premier for EXPAREL® (bupivacaine liposome
injectable suspension).
This collaboration is aimed at improving patient care and
optimizing cost savings to healthcare organizations and will allow
Premier members to access EXPAREL, a single-dose local and regional
analgesic that provides prolonged postsurgical pain control while
reducing reliance on opioids.
“Premier has an impressive network of U.S. hospitals and health
systems, and this collaboration provides Pacira an excellent
opportunity to expand reach while improving patient safety and
care,” said Frank D. Lee, Chief Executive Officer of Pacira
BioSciences. “We are proud to collaborate with organizations like
Premier as we continue to advance our mission to provide a
non-opioid pain management option to as many patients as
possible.”
Pacira and Premier share the common goals of advancing
innovation, improving patient care, and pursuing value in
healthcare. This collaboration will allow Pacira to further achieve
these important objectives while making a lasting impact on
healthcare providers and patients across the country.
Premier is a leading healthcare improvement company, uniting an
alliance of approximately 4,350 U.S. hospitals and 300,000 other
providers to transform healthcare. With integrated data and
analytics, collaboratives, supply chain solutions, consulting and
other services, Premier enables better care and outcomes at a lower
cost.
About Pacira BioSciences Pacira BioSciences,
Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option
to as many patients as possible to redefine the role of opioids as
rescue therapy only. The company is also developing innovative
interventions to address debilitating conditions involving the
sympathetic nervous system, such as cardiac electrical storm,
chronic pain, and spasticity. Pacira has three commercial-stage
non-opioid treatments: EXPAREL® (bupivacaine liposome injectable
suspension), a long-acting, local analgesia currently approved for
postsurgical pain management; ZILRETTA® (triamcinolone acetonide
extended-release injectable suspension), an extended-release,
intra-articular, injection indicated for the management of
osteoarthritis knee pain; and ioveraº®, a novel, handheld device
for delivering immediate, long-acting, drug-free pain control using
precise, controlled doses of cold temperature to a targeted nerve.
To learn more about Pacira, including the corporate mission to
reduce overreliance on opioids, visit www.pacira.com.
About EXPAREL® EXPAREL (bupivacaine liposome
injectable suspension) is indicated to produce postsurgical local
analgesia via infiltration in patients aged 6 years and older, and
postsurgical regional analgesia via an interscalene brachial plexus
block in adults, a sciatic nerve block in the popliteal fossa in
adults, and an adductor canal block in adults. The safety and
effectiveness of EXPAREL have not been established to produce
postsurgical regional analgesia via other nerve blocks besides an
interscalene brachial plexus nerve block, a sciatic nerve block in
the popliteal fossa, or an adductor canal block. The product
combines bupivacaine with multivesicular liposomes, a proven
product delivery technology that delivers medication over a desired
time period. EXPAREL represents the first and only multivesicular
liposome local anesthetic that can be utilized in the peri- or
postsurgical setting. By utilizing the multivesicular liposome
platform, a single dose of EXPAREL delivers bupivacaine over time,
providing significant reductions in cumulative pain scores with up
to a 78 percent decrease in opioid consumption; the clinical
benefit of the opioid reduction was not demonstrated. Additional
information is available at www.EXPAREL.com.
Important Safety Information about EXPAREL for
PatientsEXPAREL should not be used in obstetrical
paracervical block anesthesia. In studies in adults where EXPAREL
was injected into a wound, the most common side effects were
nausea, constipation, and vomiting. In studies in adults where
EXPAREL was injected near a nerve, the most common side effects
were nausea, fever, and constipation. In the study where EXPAREL
was given to children, the most common side effects were nausea,
vomiting, constipation, low blood pressure, low number of red blood
cells, muscle twitching, blurred vision, itching, and rapid
heartbeat. EXPAREL can cause a temporary loss of feeling and/or
loss of muscle movement. How much and how long the loss of feeling
and/or muscle movement depends on where and how much of EXPAREL was
injected and may last for up to 5 days. EXPAREL is not recommended
to be used in patients younger than 6 years old for injection into
the wound, for patients younger than 18 years old for injection
near a nerve, and/or in pregnant women. Tell your health care
provider if you or your child has liver disease, since this may
affect how the active ingredient (bupivacaine) in EXPAREL is
eliminated from the body. EXPAREL should not be injected into the
spine, joints, or veins. The active ingredient in EXPAREL can
affect the nervous system and the cardiovascular system; may cause
an allergic reaction; may cause damage if injected into the joints;
and can cause a rare blood disorder.
Investor Contact:
Susan Mesco, (973) 451-4030
susan.mesco@pacira.com
Media Contact:
Sara Marino, (973) 248-7005
Sara.marino@pacira.com
Pacira BioSciences (NASDAQ:PCRX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Pacira BioSciences (NASDAQ:PCRX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024